Substituents Based on Pharmacogenomics with Highly Variable Prognoses

[摘要] Pharmacogenomics is critical for personalised drug therapy and is becoming increasingly important in precision medicine decision-making.However, pharmacogenomics-based molecular subtypes and their potential clinical significance in Lung Adenocarcinoma remain largelyunexplored (LUAD). Three reproducible molecular subtypes were discovered, each of which was an independent prognostic factor and wasstrongly associated with stage, survival status, and accepted molecular subtypes. Non-Small Cell Lung Cancer (NSCLC) is a malignanttumour with a high incidence and cancer-related mortality, the most common pathological subclass being Lung Adenocarcinoma (LUAD).Many FDA-approved drugs are available for LUAD patients, including chemotherapy agents, targeted agents, and Immune CheckpointBlockers (ICBs). For NSCLC patients who do not have driver mutations, platinum-based chemotherapy is the primary first-line treatment.

[学科分类] 药理学